Zenocutuzumab治疗NRG1融合阳性胆管癌的疗效与耐受性:eNRGy II期试验
eNRGy是一项单臂II期研究,评估Zenocutuzumab(HER2×HER3双特异性抗体)在晚期NRG1融合阳性实体瘤中的疗效。本文报告22例NRG1融合阳性胆管癌患者,既往接受中位1线治疗,客观缓解率为36.8%(95%CI 16.3-61.6),中位缓解持续时间7.4个月,中位无进展生存期9.2个月,安全性良好。
要点
- Zenocutuzumab在经治NRG1融合阳性胆管癌中客观缓解率达36.8%(95%CI 16.3-61.6)。
- 中位缓解持续时间7.4个月,中位无进展生存期9.2个月,显示持久抗肿瘤活性。
- 治疗相关不良事件多为1-2级,最常见腹泻(27.3%)、疲劳(18.2%)和恶心(13.6%)。
核心结论
- Zenocutuzumab在晚期NRG1融合阳性胆管癌中显示出具有临床意义且持久的抗肿瘤活性,并具有有利的安全性特征。
研究设计与样本
- eNRGy是一项单臂II期研究,纳入22例晚期NRG1融合阳性胆管癌患者,年龄≥18岁,既往接受过标准治疗或不适合标准治疗。
- 患者接受Zenocutuzumab 750 mg静脉输注,每2周一次。
- 主要终点为研究者评估的客观缓解率(RECIST v1.1),次要终点包括缓解持续时间、临床获益率、无进展生存期和安全性。
主要发现
- 截至2025年7月31日,22例患者入组,中位年龄57.5岁,既往接受中位1.0线(范围0-6)治疗;有肿瘤亚型数据的18例均为肝内胆管癌。
- 3例患者不符合方案定义的疗效分析标准,可评估的19例中7例缓解,客观缓解率为36.8%(95%CI 16.3-61.6)。
- 中位缓解持续时间为7.4个月,中位起效时间为1.9个月;临床获益率为57.9%(95%CI 33.5-79.7)。
- 中位无进展生存期为9.2个月(95%CI 3.9-11.1)。
- 大多数治疗相关不良事件为1-2级,最常见为腹泻(27.3%)、疲劳(18.2%)和恶心(13.6%);1例发生3级贫血,无患者因不良事件终止治疗。
临床怎么用
- 对于既往经治的晚期NRG1融合阳性胆管癌患者,Zenocutuzumab可考虑作为一种靶向治疗选择。
局限性
- 本研究为单臂II期试验,样本量较小(22例),缺乏随机对照。
- 疗效分析仅纳入19例可评估患者,3例因不符合方案标准被排除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Presently, to our knowledge, there are no approved targeted therapies for neuregulin 1 gene fusion-positive (NRG1+) cholangiocarcinoma. Zenocutuzumab, a HER2 × HER3 bispecific antibody, is approved for previously treated, advanced/metastatic NRG1+ non-small cell lung cancer and pancreatic adenocarcinoma. Here, we report results for 22 patients with NRG1+ cholangiocarcinoma in the eNRGy trial. METHODS: eNRGy is a single-arm, phase II study of zenocutuzumab in advanced NRG1+ solid tumors. Patients were age 18 years and older and previously treated with or unsuitable for standard therapy. Zenocutuzumab 750 mg was administered intravenously once every 2 weeks. The primary end point was investigator-assessed overall response rate (ORR; RECIST v1.1). Secondary end points included duration of response (DOR), clinical benefit rate (CBR), progression-free survival (PFS), and safety. RESULTS: As of July 31, 2025, 22 patients (median age 57.5 years) with advanced NRG1+ cholangiocarcinoma were enrolled and had received a median of 1.0 (range, 0-6) prior therapies. In the 18 patients with tumor subtype data available, all had intrahepatic cholangiocarcinoma. Three patients did not meet the protocol-defined criteria for inclusion in the efficacy analysis. Seven of 19 patients achieved a response, resulting in an ORR of 36.8% (95% CI, 16.3 to 61.6). The median DOR was 7.4 months and the median time to response was 1.9 months. The CBR was 57.9% (95% CI, 33.5 to 79.7). Median PFS was 9.2 months (95% CI, 3.9 to 11.1). Most treatment-related adverse events (TRAEs) were grade 1 and 2, and the most common were diarrhea (27.3%), fatigue (18.2%), and nausea (13.6%). One patient had a grade 3 TRAE of anemia. No patients discontinued treatment due to an AE. CONCLUSION: Zenocutuzumab demonstrated clinically meaningful and durable antitumor activity with a favorable safety profile in patients with advanced NRG1+ cholangiocarcinoma.
引用
- Cleary JM, Springfeld C, Arnold D, et al. Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial. J Clin Oncol. 2026. PMID: 42385125. doi:10.1200/JCO-25-03128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。